



Research Advances in Kidney Diseases and Sepsis

Guest Editor:

Dr. Eiichi Sato

Division of Nephrology,
Department of Internal Medicine,
Shinmatsudo Central General
Hospital, Matsudo, Chiba, Japan

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Sepsis and kidney diseases have a strong interrelationship, as they mutually increase the risk of one another. Kidney disease can contribute to the development of sepsis, particularly in individuals undergoing dialysis who possess a vascular access site such as a catheter, graft or fistula beneath their skin and within a blood vessel. This access point provides an avenue for pathogens to directly enter the bloodstream. Furthermore, chronic kidney disease can compromise the immune system's functionality, thereby elevating susceptibility to severe infections. Additionally, certain medications utilized post-kidney transplant surgery (such as anti-rejection drugs) may weaken the immune response. Infections can arise from kidney stones and potentially disseminate throughout the body, leading to sepsis. Sepsis can lead to systemic dysfunction, resulting in multi-organ failure, often initiating with renal impairment. Hypotension may ensue, leading to compromised perfusion of oxygen and nutrients to the kidneys. Additionally, intravascular coagulation can impede renal oxygenation.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI